PIN1 and acute myeloid leukemia: The ability of ATRA to inhibit Pin1 function has been confirmed in breast cancer24,39 and liver cancer24,40,41 even using a different ATRA controlled release formulation42, and acute myeloid leukemia (AML)43, as well as in lupus44 and asthma45.